Key finding
Semaglutide led to a greater increase in the number of VR cells: +34.8% vs +0.8% for usual care; P = .036.
The study evaluated the effects of semaglutide on vascular regenerative cell content in individuals with type 2 diabetes, finding significant increases compared to usual care.
Evidence strength
Moderate confidence
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Quick read
The essential study design details in one scan.
Population
Young Adult (19–39), Middle Aged (40-64), Male, Female, Asia-Pacific (APAC), with T2 Diabetes
Intervention
Semaglutide, Usual care
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Primary outcome
vascular regenerative cell content (ALDH hi SSC low)
Comparator
Usual Care
Plain-language summary
A plain-language read of the study's main message and where it applies.
Study focus
The study evaluated the effects of semaglutide on vascular regenerative cell content in individuals with type 2 diabetes, finding significant increases compared to usual care.
The findings highlight the potential of semaglutide not only in managing blood sugar levels but also in enhancing vascular health in individuals with type 2 diabetes. By increasing vascular regenerative cells, semaglutide may help reduce complications associated with diabetes, such as cardiovascular diseases. This could lead to improved patient outcomes and inform treatment strategies for diabetes management.
The study's sample size may limit the generalizability of the findings. The duration of the intervention could affect long-term outcomes. Potential confounding factors were not fully explored.
Published in
Publication details and source links for this paper.
Brady P, Fallon D, Arianna ZH, et al. Semaglutide Increases Circulating Vascular Regenerative Cell Content in Individuals with Type 2 Diabetes. European Heart Journal. 2026;47(10):1171-1182. doi:10.1093/eurheartj/ehaf690
Save this study and add notes to your research library.
Semaglutide increased vascular regenerative cell content by 34.8% compared to 0.8% for usual care (P = .036).
Semaglutide increased pan-haematopoietic myeloid progenitors by 40.1% versus 2.8% for usual care (P = .017).
Semaglutide increased endothelial precursors by 66.2% while usual care decreased them by 2.3% (P = .037).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Semaglutide, Usual care and Change in vascular regenerative cell content (ALDH hi SSC low), endothelial precursors (ALDH hi SSC low CD34 + CD133 + CD45), granulocyte precursors (ALDH hi SSC hi), and 2 more.
This study contributes evidence to
Primary intervention
Semaglutide
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
1
Related topics
6
Evidence pairs
42
Related studies
Evidence topic
Contributes evidence
Core evidence
The primary outcomes reported in this study.
Semaglutide → Change in vascular regenerative cell content (ALDH hi SSC low)
Semaglutide → Change in vascular regenerative cell content (ALDH hi SSC low)
Evidence profile
Semaglutide → endothelial precursors (ALDH hi SSC low CD34 + CD133 + CD45)
Semaglutide → endothelial precursors (ALDH hi SSC low CD34 + CD133 + CD45)
Evidence profile
Semaglutide → granulocyte precursors (ALDH hi SSC hi)
Semaglutide → granulocyte precursors (ALDH hi SSC hi)
Evidence profile
Semaglutide → pan-haematopoietic myeloid progenitors (ALDH hi SSC low CD45 +)
Semaglutide → pan-haematopoietic myeloid progenitors (ALDH hi SSC low CD45 +)
Evidence profile
Semaglutide → serum proteins involved in pro-inflammatory pathways
Semaglutide → serum proteins involved in pro-inflammatory pathways
Evidence profile
Usual care → Change in vascular regenerative cell content (ALDH hi SSC low)
Usual care → Change in vascular regenerative cell content (ALDH hi SSC low)
Evidence profile
Create a free account to access effectiveness ratings, evidence strength and depth scores, consistency analysis, and direct links to all supporting studies.
Create a free account to unlock the bias score, detailed effectiveness analysis, and clinical outcomes for this study.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and endothelial precursors (ALDH hi SSC low CD34 + CD133 + CD45), GLP-1 Receptor Agonists and pan-haematopoietic myeloid progenitors (ALDH hi SSC low CD45 +).
This study contributes to the evidence on the following intervention-outcome relationships.
Curated evidence collections and hubs this study is part of.
All studies measuring endothelial precursors (ALDH hi SSC low CD34 + CD133 + CD45)
Measures endothelial precursors (ALDH hi SSC low CD34 + CD133 + CD45) as a key outcome.
All studies on GLP-1 Receptor Agonists
Contributes to GLP-1 Receptor Agonists evidence base.
All studies measuring pan-haematopoietic myeloid progenitors (ALDH hi SSC low CD45 +)
Measures pan-haematopoietic myeloid progenitors (ALDH hi SSC low CD45 +) as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in the evidence archive.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Semaglutide appears to improve Change in vascular regenerative cell content (ALDH hi SSC low).
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Change in vascular regenerative cell content (ALDH hi SSC low)
EvidenceScore™ Emerging | EvidenceScore™ 54.5 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Semaglutide appears to improve endothelial precursors (ALDH hi SSC low CD34 + CD133 + CD45).
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
endothelial precursors (ALDH hi SSC low CD34 + CD133 + CD45)
EvidenceScore™ Emerging | EvidenceScore™ 54.5 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Semaglutide appears to improve pan-haematopoietic myeloid progenitors (ALDH hi SSC low CD45 +).
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
pan-haematopoietic myeloid progenitors (ALDH hi SSC low CD45 +)
EvidenceScore™ Emerging | EvidenceScore™ 54.5 | strong positive | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Usual care for Change in vascular regenerative cell content (ALDH hi SSC low).
ConsensusScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Change in vascular regenerative cell content (ALDH hi SSC low)
EvidenceScore™ Limited | EvidenceScore™ 37.0 | neutral | ConsensusScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, archive views, and research summaries.
Open broader archive views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
